JP2023549533A5 - - Google Patents
Info
- Publication number
- JP2023549533A5 JP2023549533A5 JP2023528761A JP2023528761A JP2023549533A5 JP 2023549533 A5 JP2023549533 A5 JP 2023549533A5 JP 2023528761 A JP2023528761 A JP 2023528761A JP 2023528761 A JP2023528761 A JP 2023528761A JP 2023549533 A5 JP2023549533 A5 JP 2023549533A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- solvate
- hydrogen
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113691P | 2020-11-13 | 2020-11-13 | |
| US63/113,691 | 2020-11-13 | ||
| US202163215818P | 2021-06-28 | 2021-06-28 | |
| US63/215,818 | 2021-06-28 | ||
| PCT/US2021/072405 WO2022104383A1 (en) | 2020-11-13 | 2021-11-15 | Pharmacological agents for treating conditions of the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549533A JP2023549533A (ja) | 2023-11-27 |
| JP2023549533A5 true JP2023549533A5 (enExample) | 2024-11-25 |
Family
ID=81601792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528761A Pending JP2023549533A (ja) | 2020-11-13 | 2021-11-15 | 眼の状態を処置するための薬理剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240000812A1 (enExample) |
| EP (1) | EP4243798A4 (enExample) |
| JP (1) | JP2023549533A (enExample) |
| CA (1) | CA3202073A1 (enExample) |
| MX (1) | MX2023005675A (enExample) |
| WO (1) | WO2022104383A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872236B2 (en) | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| WO2025090994A1 (en) * | 2023-10-26 | 2025-05-01 | Plex Pharmaceuticals, Inc. | Compositions for treating cataracts and/or presbyopia eye diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE439863T1 (de) * | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| JP6068484B2 (ja) * | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． | トランスサイレチン関連アミロイドーシスの新規療法 |
| WO2013098416A2 (fr) * | 2011-12-30 | 2013-07-04 | Ecole Nationale Superieure De Chimie De Clermont Ferrand | Composes anti-douleur |
| WO2014164667A1 (en) * | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| US20160317474A1 (en) * | 2013-12-18 | 2016-11-03 | Emory University | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects |
| US11872236B2 (en) * | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| EP3683618A1 (en) * | 2019-01-21 | 2020-07-22 | Essilor International (Compagnie Generale D'optique) | System and method for demonstrating an optical disorder |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| JP2024520837A (ja) * | 2021-06-08 | 2024-05-24 | プレックビジョン、バイオテクノロジーズ、リミテッド | ダニの抑制又は滅殺及び眼球乾燥症の治療におけるｃｙｐ４５０阻害剤の使用 |
-
2021
- 2021-11-15 WO PCT/US2021/072405 patent/WO2022104383A1/en not_active Ceased
- 2021-11-15 US US18/037,021 patent/US20240000812A1/en active Pending
- 2021-11-15 CA CA3202073A patent/CA3202073A1/en active Pending
- 2021-11-15 EP EP21893092.3A patent/EP4243798A4/en active Pending
- 2021-11-15 JP JP2023528761A patent/JP2023549533A/ja active Pending
- 2021-11-15 MX MX2023005675A patent/MX2023005675A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020023528A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| JP2024026244A5 (enExample) | ||
| JP2022108241A5 (enExample) | ||
| JP2018070614A5 (enExample) | ||
| JP2022137237A5 (enExample) | ||
| JP2008540532A5 (enExample) | ||
| JP2015025011A5 (enExample) | ||
| JP2005505506A5 (enExample) | ||
| JP2006501295A5 (enExample) | ||
| JP2023511349A5 (enExample) | ||
| CA3025720A1 (en) | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1 -({4-[2-oxopyridin-1 -yl)methyl]phenyl} methyl) pyrazole -4-carboxamide as kallikrein inhibitors | |
| BRPI0720355A2 (pt) | Composições oftálmicas para o tratamento de presbiopia, bem como uso das mesmas | |
| JP2023518777A5 (enExample) | ||
| JP2025507292A5 (enExample) | ||
| JP2024545787A5 (enExample) | ||
| JP2023524504A5 (enExample) | ||
| JP5734952B2 (ja) | 新規なｅｐ４アゴニスト | |
| JP2005526773A5 (enExample) | ||
| JP2008540533A5 (enExample) | ||
| JP2024524433A5 (enExample) | ||
| JP2023510865A5 (enExample) | ||
| JP2021510168A5 (enExample) | ||
| JP4849288B2 (ja) | 点眼剤及び涙液膜の安定化剤 | |
| JP2021532183A5 (enExample) |